Short Interest in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Increases By 10.7%

Celldex Therapeutics, Inc. (NASDAQ:CLDX) saw a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 8,090,000 shares, an increase of 10.7% from the December 15th total of 7,310,000 shares. Based on an average daily volume of 1,010,000 shares, the days-to-cover ratio is currently 8.0 days.

Insider Buying and Selling at Celldex Therapeutics

In related news, CEO Anthony S. Marucci purchased 11,500 shares of the firm’s stock in a transaction on Monday, November 11th. The shares were bought at an average price of $26.82 per share, for a total transaction of $308,430.00. Following the acquisition, the chief executive officer now directly owns 40,284 shares in the company, valued at $1,080,416.88. This trade represents a 39.95 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this link. 3.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Celldex Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. SG Americas Securities LLC increased its position in shares of Celldex Therapeutics by 24.4% in the 4th quarter. SG Americas Securities LLC now owns 25,283 shares of the biopharmaceutical company’s stock worth $639,000 after purchasing an additional 4,967 shares during the last quarter. Mirador Capital Partners LP increased its position in shares of Celldex Therapeutics by 2.9% in the 4th quarter. Mirador Capital Partners LP now owns 119,492 shares of the biopharmaceutical company’s stock worth $3,020,000 after purchasing an additional 3,345 shares during the last quarter. Teachers Retirement System of The State of Kentucky increased its position in shares of Celldex Therapeutics by 5.1% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 42,628 shares of the biopharmaceutical company’s stock worth $1,449,000 after purchasing an additional 2,070 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Celldex Therapeutics by 0.4% in the 3rd quarter. Geode Capital Management LLC now owns 1,540,513 shares of the biopharmaceutical company’s stock worth $52,372,000 after purchasing an additional 6,557 shares during the last quarter. Finally, Barclays PLC increased its position in shares of Celldex Therapeutics by 140.7% in the 3rd quarter. Barclays PLC now owns 130,381 shares of the biopharmaceutical company’s stock worth $4,431,000 after purchasing an additional 76,207 shares during the last quarter.

Analyst Ratings Changes

Several research firms recently weighed in on CLDX. Wells Fargo & Company upgraded shares of Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 26th. Cantor Fitzgerald restated an “overweight” rating and set a $67.00 target price on shares of Celldex Therapeutics in a report on Thursday, January 2nd. The Goldman Sachs Group began coverage on shares of Celldex Therapeutics in a report on Monday, September 30th. They set a “neutral” rating and a $45.00 target price on the stock. Wolfe Research lowered shares of Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a report on Friday, September 27th. Finally, Citigroup assumed coverage on shares of Celldex Therapeutics in a research note on Monday, October 7th. They set a “buy” rating and a $70.00 price target on the stock. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $62.25.

Celldex Therapeutics Price Performance

Celldex Therapeutics stock traded up $1.02 during midday trading on Friday, hitting $23.78. 854,667 shares of the stock were exchanged, compared to its average volume of 852,336. Celldex Therapeutics has a 1 year low of $22.17 and a 1 year high of $53.18. The firm has a market cap of $1.58 billion, a P/E ratio of -9.25 and a beta of 1.62. The company has a 50 day moving average price of $25.80 and a two-hundred day moving average price of $31.84.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.